Vir Biotechnology Inc. (VIR) Misses Q4 EPS by 41c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley more than doubles Lenovo price target on AI-driven growth
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season